Related Experiment Video
Updated: Feb 21, 2026
06:55
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
15.4K
Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target
Jin-Liern Hong1, Michele Jonsson Funk1, Robert LoCasale2
1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
American Journal of Epidemiology
|October 12, 2017
Summary
Statins like rosuvastatin may benefit patients with high-sensitivity C-reactive protein, but real-world effectiveness requires further study. This research generalizes trial findings to broader populations using real-world data.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Real-World Evidence
Background:
- The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial established statin efficacy in specific patient groups.
- Generalizability of JUPITER findings to real-world populations with elevated high-sensitivity C-reactive protein (hs-CRP) and normal low-density lipoprotein cholesterol (LDL-C) remains uncertain.
Purpose of the Study:
- To assess the generalizability of JUPITER trial results regarding rosuvastatin's cardiovascular risk reduction to a real-world population.
- To investigate the impact of missing data and standardization methods on trial outcome generalizability.
Main Methods:
- Utilized the UK Clinical Practice Research Datalink (CPRD) database (2001-2014) for a real-world population.
- Employed multiple imputation for missing baseline characteristics in the CPRD.
- Weighted and standardized JUPITER trial participants to represent the CPRD population.
Main Results:
- The JUPITER trial showed a 3-year cardiovascular risk difference of -2.0% with rosuvastatin.
- Standardizing to the imputed CPRD population yielded a 3-year risk difference of -2.7% (95% CI: -5.8, 0.4).
- Standardizing to the CPRD population without missing data resulted in a 3-year risk difference of -1.7% (95% CI: -3.5, 0.1).
Conclusions:
- Real-world effectiveness of rosuvastatin in the JUPITER-eligible population may differ from trial findings.
- This study highlights methods for assessing trial generalizability using real-world data, addressing challenges posed by missing data.
- Further research is needed to confirm statin benefits in diverse, real-world patient cohorts.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
830
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
830
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
489
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
489
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:52Regression Toward the Mean
7.2K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
7.2K
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
199
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
199
01:25Strategies for Assessing and Addressing Confounding
452
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
452